Search research articles
Contact Us
Filters
Showing results (81-90 of 174) with videos related to
Page
of 18
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
December 11, 2008
Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the 'GISCAD-alternating schedule' study findings
Mario Mandalà, Sandro Barni, Irene Floriani, et al.
Journal of the National Cancer Institute
|
October 30, 2012
Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer
Arnaud D Roth, Mauro Delorenzi, Sabine Tejpar, et al.
Current Colorectal Cancer Reports
|
September 14, 2013
The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status
Thierry André, Timothy Iveson, Roberto Labianca, et al.
European Urology
|
February 16, 2008
Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study
Giuseppe Di Lorenzo, William D Figg, Sophie D Fossa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 2007
Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy
Mario Scartozzi, Italo Bearzi, Chiara Pierantoni, et al.
Tumori
|
December 16, 2006
Capecitabine and mitomycin C may be an effective treatment option for third-line chemotherapy in advanced colorectal cancer
Mario Scartozzi, Alfredo Falcone, Francesca Pucci, et al.
Journal of the National Cancer Institute
|
November 1, 2014
ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer
Lindsay A Renfro, Axel Grothey, Yuan Xue, et al.
Clinical Drug Investigation
|
September 12, 2008
Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting
Francesco Di Costanzo, Roberto Ravasio, Alberto Sobrero, et al.
Journal of the National Cancer Institute
|
May 21, 2011
DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy
Frank A Sinicrope, Nathan R Foster, Stephen N Thibodeau, et al.
BMC Cancer
|
August 29, 2009
Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis
Mario Scartozzi, Italo Bearzi, Alessandra Mandolesi, et al.
Page
of 18
Search research articles
Search
Showing results (81-90 of 174) with videos related to
Sort By:
Page
of 18
European Journal of Cancer (Oxford, England : 1990)
|
December 11, 2008
Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the 'GISCAD-alternating schedule' study findings
Mario Mandalà, Sandro Barni, Irene Floriani, et al.
Journal of the National Cancer Institute
|
October 30, 2012
Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer
Arnaud D Roth, Mauro Delorenzi, Sabine Tejpar, et al.
Current Colorectal Cancer Reports
|
September 14, 2013
The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status
Thierry André, Timothy Iveson, Roberto Labianca, et al.
European Urology
|
February 16, 2008
Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study
Giuseppe Di Lorenzo, William D Figg, Sophie D Fossa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 2007
Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy
Mario Scartozzi, Italo Bearzi, Chiara Pierantoni, et al.
Tumori
|
December 16, 2006
Capecitabine and mitomycin C may be an effective treatment option for third-line chemotherapy in advanced colorectal cancer
Mario Scartozzi, Alfredo Falcone, Francesca Pucci, et al.
Journal of the National Cancer Institute
|
November 1, 2014
ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer
Lindsay A Renfro, Axel Grothey, Yuan Xue, et al.
Clinical Drug Investigation
|
September 12, 2008
Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting
Francesco Di Costanzo, Roberto Ravasio, Alberto Sobrero, et al.
Journal of the National Cancer Institute
|
May 21, 2011
DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy
Frank A Sinicrope, Nathan R Foster, Stephen N Thibodeau, et al.
BMC Cancer
|
August 29, 2009
Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis
Mario Scartozzi, Italo Bearzi, Alessandra Mandolesi, et al.
Page
of 18